Revealed: How Ireland has worst access for new cancer drugs

The situation impacts public patients and those with private health insurance as health insurers do not typically fund or provide access to medicines that are not funded by the HSE.

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
15th September, 2017
Oliver O’Connor, chief executive of the Irish Pharmaceutical Healthcare Association (IPHA) and Simon Harris TD, Minister for Health

Irish cancer patients are being denied access to innovative new medicines that are often available in other EU countries.

Just 20 per cent of new cancer medicines launched internationally in 2014 and 2015 were available to Irish patients by 2016, new figures show.

The low Irish figure compares with 76 per cent in Germany and 71 per cent in Austria. In Denmark, 67 per cent were reimbursed.

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Butler urges completion of eating disorder unit as ‘matter of priority’

Specialist eating disorder unit delayed until at least mid-2022

Updated cost of new children’s hospital still ‘confidential’

Hospital group boards to be disbanded to make way for regional health areas